News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
3,257 Results
Type
Article (849)
Company Profile (2)
Press Release (2406)
Multimedia
Podcasts (16)
Webinars (1)
Section
Business (1286)
Career Advice (20)
Deals (181)
Drug Delivery (10)
Drug Development (609)
Employer Resources (10)
FDA (94)
Job Trends (177)
News (2003)
Policy (148)
Tag
Academia (10)
Accelerated approval (1)
Alliances (184)
ALS (2)
Alzheimer's disease (7)
Antibody-drug conjugate (ADC) (1)
Approvals (90)
Artificial intelligence (3)
Autoimmune disease (8)
Bankruptcy (2)
Best Places to Work (111)
BIOSECURE Act (2)
Biosimilars (1)
Biotechnology (1)
Breast cancer (1)
Cancer (13)
Cardiovascular disease (7)
Career advice (16)
CAR-T (7)
Cell therapy (24)
Clinical research (424)
Collaboration (11)
Compensation (3)
Complete response letters (2)
COVID-19 (13)
CRISPR (30)
C-suite (29)
Cystic fibrosis (39)
Data (25)
Diabetes (7)
Diagnostics (5)
Diversity, equity & inclusion (2)
Drug discovery (5)
Drug pricing (10)
Duchenne muscular dystrophy (4)
Earnings (386)
Editorial (3)
Employer branding (6)
Employer resources (8)
Events (466)
Executive appointments (19)
FDA (112)
Funding (21)
Gene editing (48)
Gene therapy (49)
GLP-1 (20)
Government (39)
Guidances (4)
Healthcare (43)
Huntington's disease (2)
IgA nephropathy (16)
Immunology and inflammation (9)
Immuno-oncology (2)
Indications (1)
Infectious disease (13)
Intellectual property (1)
Interviews (3)
IPO (54)
Job creations (68)
Job search strategy (13)
JPM (2)
Labor market (2)
Layoffs (6)
Leadership (2)
Legal (18)
Lung cancer (3)
Lymphoma (1)
Manufacturing (8)
Medical device (15)
Medtech (15)
Mergers & acquisitions (126)
Metabolic disorders (18)
mRNA (7)
Multiple sclerosis (2)
Neurodegenerative disease (6)
Neuropsychiatric disorders (1)
Neuroscience (20)
NextGen: Class of 2026 (51)
Non-profit (14)
Now hiring (4)
Obesity (10)
Opinion (14)
Pain (31)
Parkinson's disease (1)
Partnered (1)
Patents (1)
Patient recruitment (2)
People (641)
Pharmaceutical (1)
Phase 1 (153)
Phase 2 (233)
Phase 3 (158)
Pipeline (55)
Policy (14)
Postmarket research (18)
Preclinical (36)
Radiopharmaceuticals (2)
Rare diseases (86)
Real estate (57)
Recruiting (4)
Regulatory (149)
Research institute (5)
Resumes & cover letters (5)
RSV (1)
Schizophrenia (2)
Series A (6)
Series B (2)
Sickle cell disease (35)
Special edition (2)
Spinal muscular atrophy (1)
Startups (35)
Supply chain (1)
Tariffs (6)
The Weekly (16)
Vaccines (8)
Venture capital (4)
Weight loss (5)
Date
Today (1)
Last 7 days (4)
Last 30 days (19)
Last 365 days (197)
2026 (79)
2025 (218)
2024 (270)
2023 (222)
2022 (231)
2021 (254)
2020 (260)
2019 (197)
2018 (183)
2017 (221)
2016 (137)
2015 (210)
2014 (79)
2013 (67)
2012 (88)
2011 (122)
2010 (67)
Location
Africa (13)
Alabama (1)
Asia (96)
Australia (19)
California (38)
Canada (13)
China (15)
Colorado (1)
Europe (516)
Illinois (4)
Japan (2)
Maryland (6)
Massachusetts (193)
Minnesota (1)
Montana (1)
New Hampshire (5)
New Jersey (5)
New York (11)
North Carolina (9)
Northern California (15)
Ohio (2)
Pennsylvania (5)
South America (13)
Southern California (17)
Texas (2)
United States (276)
Utah (1)
Washington State (4)
3,257 Results for "vertex".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Earnings
Vertex’s quiet Q1 is calm before potentially ‘iconic’ renal evolution
While some analysts may regard Vertex Pharmaceuticals’ first quarter results as “unremarkable,” BMO Capital Markets wrote on Monday, the second half of 2026 could be big for the biotech, with the potential approval of IgAN therapy povetacicept.
May 5, 2026
·
2 min read
·
Tristan Manalac
IgA nephropathy
Vertex’s Nephropathy Asset Delivers ‘Strong’ Late-Stage Data, Clears Path to FDA
Vertex Pharmaceuticals has a rolling biologics license application with the FDA for povetacicept in IgA nephropathy. With new data from RAINIER, the biotech expects to complete its submission by the end of March.
March 10, 2026
·
2 min read
·
Tristan Manalac
Earnings
All Eyes on Vertex’s Kidney Franchise, as Painkiller Journavx Tops Half a Million Scripts
Analysts are keeping a close eye on Vertex’s kidney disease portfolio, anchored by the IgAN drug povetacicept, as its nonopioid painkiller Journavx is poised for “incremental” growth in the first half 2026, according to BMO Capital Markets.
February 13, 2026
·
2 min read
·
Tristan Manalac
Earnings
Vertex’s New Products Dim as Analysts Eye Kidney Portfolio
The potential approval of Vertex’s IgAN therapy povetacicept in 2026 comes amid launch headwinds for the company’s non-opioid pain medicine Journavx and gene therapy Casgevy.
November 4, 2025
·
5 min read
·
Tristan Manalac
Gene therapy
Vertex, CRISPR Set Lofty Goal for Casgevy Gene Therapy as Patient Starts Ramp
Following over a year of slow uptake, Vertex Pharmaceuticals and CRISPR Therapeutics expect Casgevy revenues to nearly triple in 2026, as patient access to the sickle cell disease and beta thalassemia gene therapy grows.
February 13, 2026
·
3 min read
·
Dan Samorodnitsky
Press Releases
Vertex to Participate in Upcoming May 2026 Investor Conferences
May 12, 2026
·
1 min read
Press Releases
Vertex Reports First Quarter 2026 Financial Results
May 5, 2026
·
20 min read
Press Releases
NKF Honors Vertex with 2026 Kidney Biotech Innovation Award
May 6, 2026
·
4 min read
Business
J&J’s Duato makes 358 times his median employee; Vertex CEO makes just 80 times
BioSpace
analyzed the pay ratio across 10 major pharmaceutical companies to determine which CEOs were paid the most relative to typical employees. J&J, Eli Lilly and Pfizer once again topped the list.
May 20, 2026
·
1 min read
·
Annalee Armstrong
Press Releases
Vertex to Announce First Quarter 2026 Financial Results on May 4th
April 7, 2026
·
1 min read
1 of 326
Next
